Interventions for valvular disease and heart failure

Transcatheter edge-to-edge mitral valve repair in patients with mitral annulus calcification

EuroIntervention 2022;17:1300-1309. DOI: 10.4244/EIJ-D-21-00205

Estefanía Fernández-Peregrina
Estefanía Fernández-Peregrina1,2, MD; Isaac Pascual3, MD; Xavier Freixa4, MD, PhD; Gabriela Tirado-Conte5, MD; Rodrigo Estévez-Loureiro6, MD, PhD; Fernando Carrasco-Chinchilla7, MD; Tomás Benito-González8, MD; Lluis Asmarats1, MD, PhD; Laura Sanchís4, MD; Pilar Jiménez-Quevedo5, MD; Pablo Avanzas3, MD, PhD; Berenice Caneiro-Queija6, MD; Ana Isabel Molina-Ramos7, MD; Felipe Fernández-Vázquez8, MD, PhD; Chi-Hion Li1, MD; Eduardo Flores-Umanzor4, MD; Jordi Sans-Roselló1,2, MD; Luis Nombela-Franco5, MD, PhD; Dabit Arzamendi1,2, MD, PhD
1. Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 2. Department of Medicine, Universitat Autónoma de Barcelona, Barcelona, Spain; 3. Heart Area, Hospital Universitario Central de Asturias, Oviedo, Spain; 4. Hospital Clinic de Barcelona, Institut Clinic Cardiovascular, Barcelona, Spain; 5. Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain; 6. Interventional Cardiology Unit, Hospital Álvaro Cunqueiro, Vigo, Spain; 7. Hospital Clínico Universitario Virgen de la Victoria, CIBERCV, Málaga, Spain; 8. Department of Cardiology, University Hospital of León, León, Spain

Background: MAC is commonly found in patients affected with MR, and it is associated with high morbidity, mortality and worse cardiac surgical outcomes. Transcatheter edge-to-edge repair could be an alternative treatment, although there is little evidence in this population.

Aims: The aim of this study was to analyse the safety, efficacy and durability of MitraClip implantation in patients affected with mitral regurgitation (MR) and mitral annulus calcification (MAC).

Methods: We analysed the outcomes of 61 suitable patients affected with severe MR and moderate or severe MAC (the “MAC” group) and 791 patients with no or mild MAC (the “NoMAC” group) treated with the MitraClip device.

Results: Procedural success was similar (91.8% vs 95.1%, p=0.268, in MAC and NoMAC, respectively), with a very low rate of complications. At one-year follow-up, 90.6% of MAC and 79.5% of NoMAC patients had MR grade ≤2 (p=0.129), 80% in both groups remained in NYHA Functional Class ≤II, and a significant reduction in cardiac readmissions was observed (65% vs 78% in MAC vs NoMAC, p=0.145). One-year mortality tended to be higher in MAC patients (19.7% vs 11.3%, p=0.050), with no difference in cardiovascular mortality (15.3% vs 9.2%, p=0.129).

Conclusions: MitraClip use in selected patients with moderate or severe MAC is safe, feasible and achieves good clinical and echocardiographic results at one-year follow-up.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

chronic heart failuremitral regurgitationmitral valve repair
Read next article
Procedural and early outcomes of transcatheter edge-to-edge mitral valve repair in very elderly patients

Latest news